Cite
MLA Citation
Iain B McInnes et al.. “263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period.” Rheumatology, vol. 58, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100092355098.0x00001c